Similar Articles |
|
Pharmaceutical Executive December 1, 2008 Patrick Clinton |
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. |
Pharmaceutical Executive October 1, 2012 Gregg DiPietro |
Reforming Pharma Marketing With respect to targeting, positioning, and launching new drugs, the ACA reform stands for Adjust, Change, and Adapt. |
Pharmaceutical Executive October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
Pharmaceutical Executive February 1, 2007 |
Marketing to Professionals: Resource Allocation A Stanford professor schools pharma on professional marketing. |
Pharmaceutical Executive July 1, 2012 Al Topin |
Marketing: Why the Conversation Has Changed -- Forever At its core, pharma marketing is about conversations. Dynamic, persuasive conversations between companies and healthcare stakeholders. But one time it was simple; now it's not. |
Pharmaceutical Executive November 1, 2014 |
Sales Reps and the New Commercial Organization By rethinking the role of the sales rep and the new skills it demands, pharma companies can put themselves in a prime competitive position. |
Pharmaceutical Executive July 1, 2009 Patrick Clinton |
What to Buy In the long run, pharma wants to sell health, not just drugs. |
Pharmaceutical Executive May 1, 2012 William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Pharmaceutical Executive October 1, 2008 Patrick Clinton |
Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there? |
Pharmaceutical Executive October 1, 2008 Walter Armstrong |
The Drug Vote '08 A head-to-head comparison of the Drug Vote '08 |
Pharmaceutical Executive February 1, 2014 Anbil et al. |
Managed Markets: Positioning Your Product For Success with Pull Through Strategies A patient-centric approach to drug development delivers the benefits that actually create value |
Pharmaceutical Executive August 1, 2012 Andrea Sobrio |
Innovative Contracting: What is the Verdict? Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. Is it working? |
Pharmaceutical Executive September 1, 2011 Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
Pharmaceutical Executive March 1, 2012 Paolo De Marino |
Registering Value: Always in the Eye of the Beholder The organizational disconnect between marketing and market access is curable if both groups focus on what counts: who's making the final purchase. |
Pharmaceutical Executive March 3, 2014 Sillup & Porth |
Pharm Exec: Annual Press Audit 2014 Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years. |
Pharmaceutical Executive October 1, 2010 |
Decisive Strategy Wins the Market A clear, consistent approach to the competition can deliver big gains in market share; six decisions lead the way. |
Pharmaceutical Executive April 1, 2007 Porth & Sillup |
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. |
Pharmaceutical Executive April 1, 2005 |
Thought Leader: Better Business: Balancing Benefit, Risk, and Cost An interview with author and Harvard Medical School professor Dr. Jerry Avorn on how losing track of patient welfare and failing to address important safety problems isn't just bad science and bad ethics, it's also bad business. |
Pharmaceutical Executive October 1, 2011 |
Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare. |
Pharmaceutical Executive August 1, 2006 Patrick Clinton |
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. |
Pharmaceutical Executive April 10, 2014 |
Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler. |
The Motley Fool May 12, 2009 Brian Orelli |
Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama. |
Pharmaceutical Executive December 1, 2011 William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive September 1, 2012 Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive July 1, 2012 William Looney |
The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good. |
Pharmaceutical Executive January 1, 2012 William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive January 1, 2006 Sarah Houlton |
Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice. |
Pharmaceutical Executive April 1, 2007 Fard Johnmar |
Alternative Media: Mastering Social Media Pharma agencies are buzzing about social media tools such as blogs, podcasts, and interactive healthcare forums, but few firms really know how to make these online initiatives work. |
Pharmaceutical Executive February 1, 2011 Stan Bernard |
Are You Trained to Compete and Win? With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace |
Pharmaceutical Executive February 1, 2006 Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
Pharmaceutical Executive March 1, 2013 Sillup et al. |
Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues. |
Pharmaceutical Executive March 1, 2009 Brittany Agro |
The New Sales Force The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with, and how it's working. |
Pharmaceutical Executive April 1, 2006 Sukys & Vernick |
Direct to Consumer: Inspirational Insights Whether brand marketers are developing a current product or launching a new one, powerful consumer insights are what they need to get into the hearts and minds of their target consumers. |
Pharmaceutical Executive August 1, 2011 Bill Drummy |
The Slow Dance Toward Obsolescence Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change? |
Pharmaceutical Executive August 1, 2006 |
Introduction: Pharm Exec at 25 A pharmaceuticals magazine celebrates its 25th anniversary. |
Pharmaceutical Executive May 1, 2011 William Looney |
Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. |
Pharmaceutical Executive January 21, 2014 Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
Pharmaceutical Executive July 1, 2011 William Looney |
Truth Found in the Wrong Places More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them. |
Pharmaceutical Executive February 1, 2012 Wilcox et al. |
Sales Force Survey: Still Too Much Business as Usual? In the global battle for market share, the ability to adapt and mobilize your human assets around a responsive commercial model is a key variable of success. |
Pharmaceutical Executive January 1, 2009 Walter Armstrong |
Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges. |
Pharmaceutical Executive January 1, 2009 Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Pharmaceutical Executive March 1, 2012 Ringler & Comer |
The (Life) Science of Digital Connections Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma |
Pharmaceutical Executive October 1, 2005 |
Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies. |
Pharmaceutical Executive November 1, 2011 Jeff Schindler |
Fostering a Legacy of Leadership Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York. |
Pharmaceutical Executive January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Pharmaceutical Executive November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay |
Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole. |
Pharmaceutical Executive July 1, 2012 Jill Wechsler |
Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. |
Pharmaceutical Executive November 1, 2013 William Looney |
Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry. |
Pharmaceutical Executive March 1, 2011 Andrea LaFountain |
Where have all the Scientists Gone? With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence. |